NICE Technology Appraisals (TAs) for Children


This page details all NICE Technology Appraisals (TAs) for Children and is an interim position until the paediatric formulary is published. When the medicines are used in accordance with the NICE TA, these are formulary within BNSSG.

 

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

Atopic eczema - tacrolimus and pimerolimus

 

Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)

 

Arthritis (juvenile idiopathic) - etanercept

Arthritis (juvenile idiopathic, systemic) - tocilizumab

 

Asthma (children under 5) - inhaler devices 

Asthma (older children) - inhaler devices

Asthma (sever, persistent, allergic 6yrs and over) - omalizumab

Asthma (in children) - corticosteriods

 

Bipolar disorder - adolescents (13 years and older) -

  

Human growth hormone (somatropin) for the treatment of growth failure in children (review)

 

Renal transplantation - immunosuppressive regimens for children and adolescents

 

Schizophrenia - aripiprazole

 

NHS England Commissioning policy

 

Uveitis

D12X02 Interim Clinical Commissioning Policy: Adalimumab for Children with Severe Refractory Uveitis

 

Last updated by: Emily Knight on 03-11-2017 14:10